Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $15.3 million, a 23% increase year-over-year and a 6.5% increase from the previous quarter [6] - Adjusted EBITDA rose 20.6% to $2.8 million, or $0.05 per fully diluted share, compared to $2.4 million, or $0.04 per fully diluted share a year earlier [6] - Gross margins improved by 440 basis points to 55.5% from 51.1% in the same period last year [7][20] Business Line Data and Key Metrics Changes - Revenue from the patient affordability business grew by 219% year-over-year to $3.3 million, with claims processed increasing by 430% [7] - Plasma donor compensation revenue increased by 3.4% year-over-year to $11.4 million, despite challenges from hurricanes and staffing shortages [10][15] - Other revenue increased by 73.5% to $542,000, driven by growth in payroll, retail, and corporate incentive businesses [18] Market Data and Key Metrics Changes - The company exited Q3 with 66 active patient affordability programs, an increase of 23 programs since the end of 2023 [17] - The total number of plasma centers increased to 478, with plans to add two more by year-end [11] Company Strategy and Development Direction - The company aims to diversify revenue streams, focusing on specialty drugs and expanding its patient affordability business [9][12] - Investments in fintech solutions for healthcare payments are expected to drive long-term growth and shareholder value [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, particularly in the patient affordability segment, which is expected to become a primary revenue driver [12] - The company anticipates onboarding several new programs in Q4, including a significant account with a major pharmaceutical company [9] Other Important Information - The company expects total revenues for the full year to be between $56.5 million and $58.5 million, reflecting year-over-year growth of 20% to 24% [26] - Legal expenses related to class action and derivative lawsuits are anticipated in Q4, impacting operating expenses [27] Q&A Session Summary Question: Details on additional pharma campaigns - Management discussed the addition of cornerstone accounts and the variety of therapeutic classes covered by these accounts [33][34] Question: Average revenue per program - Management indicated that average revenue per program is not relevant due to the variability in claims volume across different programs [36] Question: Growth expectations for pharma segment in 2025 - Management expressed optimism about strong growth in the pharma segment, supported by a robust pipeline and existing client relationships [40][41] Question: Staffing shortages in plasma business - Management noted that staffing shortages are due to increased competition for labor as new centers have opened [45] Question: Market size for patient affordability services - Management estimated the total addressable market for patient affordability services to be over $500 million [46] Question: Competitive landscape and innovation - Management highlighted that the company is winning business through both competitive takeaways and innovative solutions that address unmet needs in the market [48] Question: Gross margin expectations - Management provided guidance that gross margins could improve as the patient affordability segment grows [58]

Financial Performance - Total revenues for Q3 2024 were $15.26 million, representing a 23.0% increase from Q3 2023[2] - Net income for Q3 2024 was $1.44 million, or $0.03 per diluted share, compared to $1.10 million, or $0.02 per diluted share in Q3 2023[2] - Adjusted EBITDA for Q3 2024 increased by 20.6% to $2.83 million, or $0.05 per diluted share[2] - Total revenues for the three months ended September 30, 2024, increased to $15,256,431, up 23.5% from $12,400,325 in the same period of 2023[22] - Net income for the three months ended September 30, 2024, was $1,436,837, compared to $1,100,604 for the same period in 2023, representing a 30.5% increase[22] - Adjusted EBITDA for the three months ended September 30, 2024, was $2,828,969, an increase of 20.6% from $2,345,359 in the same period of 2023[28] - The company’s diluted net income per share for the three months ended September 30, 2024, was $0.03, compared to $0.02 for the same period in 2023[22] Revenue Sources - Pharma patient affordability revenue surged by 219.1% year-over-year, contributing to 21.5% of total revenues[4][12] Operational Metrics - The company exited Q3 2024 with 478 plasma centers, a net increase of one center during the quarter[5][8] - Active patient affordability programs increased to 66, with five new programs added in Q3 2024[5][8] Profitability and Expenses - Gross profit margin improved to 55.5%, up 440 basis points from 51.1% in the prior year[6] - Selling, general and administrative expenses rose by 32.4% to $6.20 million, primarily due to increased compensation and benefits[6] - The company reported a gross profit of $8,473,314 for the three months ended September 30, 2024, compared to $6,332,118 in the same period of 2023, marking a 33.9% increase[22] - Selling, general and administrative expenses rose to $6,217,844 for the three months ended September 30, 2024, up from $4,696,509 in the same period of 2023, reflecting a 32.3% increase[22] Cash and Assets - The company ended Q3 2024 with $10.29 million in unrestricted cash and zero debt[2][10] - Cash and cash equivalents decreased to $10,293,207 as of September 30, 2024, down from $16,994,705 at December 31, 2023[24] - Accounts receivable increased significantly to $32,796,871 as of September 30, 2024, compared to $16,222,341 at December 31, 2023, reflecting a 102.5% increase[24] - Total assets grew to $166,974,064 as of September 30, 2024, up from $146,598,849 at December 31, 2023, indicating a 13.9% increase[24] - Total liabilities increased to $138,467,755 as of September 30, 2024, compared to $122,111,468 at December 31, 2023, representing a 13.4% rise[24] Future Guidance - Full-year 2024 revenue guidance is projected to be between $56.5 million and $58.5 million, with adjusted EBITDA expected between $9.0 million and $10.0 million[14]

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis ...

The Business Services group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Paysign, Inc. (PAYS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Business Services sector should help us answer this question. Paysign, Inc. is one of 317 individual stocks in the Bus ...

Group 1 - Paysign, Inc. (PAYS) has shown a year-to-date return of 67.5%, significantly outperforming the average return of 10.9% in the Business Services sector [4] - The Zacks Consensus Estimate for PAYS' full-year earnings has increased by 10.5% over the past quarter, indicating improved analyst sentiment [4] - Paysign, Inc. is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Group 2 - Paysign, Inc. is part of the Financial Transaction Services industry, which has an average return of 7.3% this year, further highlighting PAYS' strong performance [6] - Recruit Holdings Co., Ltd. (RCRRF) has also outperformed the Business Services sector with a return of 57% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5] - The Business - Information Services industry, to which Recruit Holdings belongs, has seen a return of 12.2% this year, ranking 149 in the Zacks Industry Rank [6]

cagkansayin Paysign (NASDAQ:PAYS) is a fintech company with a niche focus on healthcare, specifically Plasma donor compenssion and patient affordability programs. It is a small-cap com 《TrendSpider Ava 14,20045.44 17.56 15.00 12.50 10.00 r sa E a m d.100 e ess Price Revenue & EPS (TrendSpider) The pandemic hit its affordability hard, as seen in the image, but it also increased its revenue and size. It seems that it may finally be returning to its former glory, bu with greater revenue, a better outlook, and ...

Title of each Class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share PAYS The Nasdaq Stock Market LLC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Paysign, Inc. (NASDAQ:PAYS) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President of Patient Affordability Conference Call Participants Gary Prestopino - Barrington Research Operator Good afternoon. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Paysign Inc. Second Quarter 2024 Earnings Conference Call. After the speaker's remarks, there will be ...

Exhibit 99.1 Earnings Release Paysign, Inc. Reports Second Quarter 2024 Financial Results · Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 · Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 · Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per ...

Paysign, Inc. (NASDAQ:PAYS) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President of Patient Affordability Matt Lanford - Chief Payments Officer Conference Call Participants Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalmann Operator Good afternoon. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Paysign Inc. First Quarter 2024 E ...